SUVARI TRICIA BORGA 4
4 · Global Blood Therapeutics, Inc. · Filed Sep 6, 2022
Insider Transaction Report
Form 4
SUVARI TRICIA BORGA
Chief Legal Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2022-09-01−2,208→ 15,460 total→ Common Stock (2,208 underlying) - Exercise/Conversion
Common Stock
2022-09-01+2,763→ 42,750 total - Exercise/Conversion
Common Stock
2022-09-01+2,208→ 44,958 total - Award
Common Stock
2022-08-31$25.37/sh+385$9,767→ 39,987 total - Tax Payment
Common Stock
2022-09-01$68.15/sh−1,881$128,190→ 43,077 total - Exercise/Conversion
Restricted Stock Units
2022-09-01−2,763→ 13,814 total→ Common Stock (2,763 underlying)
Footnotes (5)
- [F1]Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
- [F3]Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,971 shares of Common Stock underlying the Reporting Person's RSUs.
- [F4]The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- [F5]The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.